Clinical Trial Update: A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I dose-escalation study update of Lipocurc in patients with advanced cancer that failed standard therapy; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Lipocurc

Snippet

Sponsor: SignPath Pharma, Inc. | Conditions: Patients w/Advanced Cancer That Failed Std of Care Therapy | Phase 1, Phase 2 | Status: COMPLETED